Bridgefront Capital LLC Invests $726,000 in Zoetis Inc. $ZTS

Bridgefront Capital LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,965 shares of the company’s stock, valued at approximately $726,000.

Several other hedge funds have also added to or reduced their stakes in the business. CIBC Asset Management Inc grew its position in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares during the last quarter. Ninety One UK Ltd boosted its stake in Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after purchasing an additional 183,686 shares during the period. Quilter Plc boosted its stake in Zoetis by 10.2% in the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after purchasing an additional 40,615 shares during the period. Finally, Swedbank AB grew its holdings in Zoetis by 60.4% in the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after buying an additional 917,598 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent research reports. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. KeyCorp initiated coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Barclays started coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Finally, Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Price Performance

Shares of NYSE ZTS opened at $115.62 on Monday. The stock has a market capitalization of $48.81 billion, a PE ratio of 19.21, a P/E/G ratio of 1.76 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a fifty day moving average price of $125.34 and a two-hundred day moving average price of $131.58. Zoetis Inc. has a fifty-two week low of $114.47 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm posted $1.40 EPS. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.